Synthetic peptide corresponding to 30 aa (GPPAAAPGHPLAPGPHPAAPSSWGPRPRRY) from the first N-terminal D1 domain of human LAG-3 (lymphocyte activation gene-3).
UniProt ID:
P18627
Source:
Purified from hybridoma tissue culture supernatant.
Species reactivity:
Human
Specificity:
Recognizes the 30 aa extra-loop of the first N-terminal D1 domain of LAG-3.
Applications:
ICC, IHC, IP, WB
Recommended Dilutions/Conditions:
Immunohistochemistry (frozen sections, 1:150) Western Blot (5µg/ml) Immunoprecipitation (10µg/ml) Suggested dilutions/conditions may not be available for all applications. Optimal conditions must be determined individually for each application.
Purity Detail:
Purified.
Formulation:
Liquid. In PBS containing 10% glycerol and 0.02% sodium azide.
Use/Stability:
Stable for at least 6 months after receipt when stored as recommended.
Handling:
Avoid freeze/thaw cycles.
Shipping:
Blue Ice
Short Term Storage:
+4°C
Long Term Storage:
-20°C
Scientific Background:
The lymphocyte activation gene-3 (LAG-3, CD223), a member of the immunoglobulin superfamily (IgSF) related to CD4, binds to the major histocompatibility complex (MHC) class II molecules but with higher affinity than CD4. Several alternative mRNA splice-variants of human LAG-3 have been described, two of them encoding potential secreted forms: LAG-3V1 (i.e. the D1-D2 domains of the protein, 36 kDa) and LAG-3V3 (D1-D3, 52 kDa). The longer form was detected by ELISA in the serum of healthy individuals as well as of tuberculosis patients with a favorable outcome. LAG-3 expression by T cell clones correlated with IFN-γ production, and hence soluble LAG-3 has been suggested as a serological marker of Th1 responses.
Regulatory Status:
RUO - Research Use Only
Western blot analysis of LAG-3 mAb (17B4) (Prod. No. ALX-804-806): Lane 1: MW marker, Lane 2: LAG-3 (human):Fc (human), (recombinant) (Prod. No. ALX-522-078).
Please mouse over
Product Literature References
Durable response of anaplastic thyroid carcinoma to FS118, a bispecific LAG-3/PD-L1 antibody, after checkpoint inhibitor progression: a case report: M.J. Kroloff, et al.; J. Immunother. Cancer 10, e005225 (2022), Abstract;
High Frequency Production of T Cell-Derived iPSC Clones Capable of Generating Potent Cytotoxic T Cells: S. Nagano, et al.; Mol. Ther. Methods Clin. Dev. 16, 126 (2019), Abstract; Full Text
Epigenomic-guided mass cytometry profiling reveals disease-specific features of exhausted CD8 T cells: B. Bengsch, et al.; Immunity 48, 1029 (2018), Abstract; Full Text
NK cell and IFN signatures are positive prognostic biomarkers for resectable pancreatic cancer: M. Hoshikawa, et al.; Biochem. Biophys. Res. Commun. 495, 2058 (2017), Abstract;
Psoriasis is characterized by deficient negative immune regulation compared to transient delayed-type hypersensitivity reactions: N. Gulati, et al.; F1000Res. 4, 149 (2015), Application(s): Immunohistochemistry, Abstract; Full Text
Specific Lymphocyte Subsets Predict Response to Adoptive Cell Therapy Using Expanded Autologous Tumor-Infiltrating Lymphocytes in Metastatic Melanoma Patients: L.G. Radvanyi, et al.; Clin. Cancer Res. 18, 6758 (2012), Application(s): FC using tumor-infiltrating lymphocytes (TIL), Abstract; Full Text
Tumor-infiltrating NY-ESO-1–specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer: J. Matsuzaki, et al.; PNAS 107, 7875 (2010), Application(s): Blocking assays using tumor-infiltrating lymphocytes (TIL), Abstract; Full Text
Human lymphocyte activation gene-3 molecules expressed by activated T cells deliver costimulation signal for dendritic cell activation: C. Casati, et al.; J. Immunol. 180, 3782 (2008), Abstract;
Rapid Suppression of Cytokine Transcription in Human CD4+CD25– T Cells by CD4+Foxp3+ Regulatory T Cells: Independence of IL-2 Consumption, TGF-β, and Various Inhibitors of TCR Signaling: N. Oberle, et al.; J. Immunol. 179, 3578 (2007), Application(s): Flow cytometry and blocking assays using human T-reg cells, Abstract; Full Text
A soluble lymphocyte activation gene-3 (sLAG-3) protein as a prognostic factor in human breast cancer expressing estrogen or progesterone receptors: F. Triebel, et al.; Cancer Lett. 235, 147 (2006), Abstract;
Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and allogeneic stem cell transplantation: R.F. Rousseau, et al.; Blood 107, 1332 (2006), Application(s): Flow cytometry using human peripheral-blood mononuclear cells (PBMCs), Abstract; Full Text
Immunological mechanisms elicited at the tumour site by lymphocyte activation gene-3 (LAG-3) versus IL-12: sharing a common Th1 anti-tumour immune pathway: E.D. Carlo, et al.; J. Pathol. 205, 82 (2005), Abstract;
Responses to Human CD40 Ligand/Human Interleukin-2 Autologous Cell Vaccine in Patients with B-Cell Chronic Lymphocytic Leukemia: E. Biagi, et al.; Clin. Cancer Res. 11, 6916 (2005), Application(s): FC using human T-reg cells and blocking assays using human CD4+/CD8+ T cells, Abstract; Full Text
The negative regulatory function of the lymphocyte-activation gene-3 co-receptor (CD223) on human T cells: L. Macon-Lemaitre and F. Triebel; Immunology 115, 170 (2005), Abstract;
T Lymphocytes infiltrating various tumour types express the MHC class II ligand lymphocyte activation gene-3 (LAG-3): role of LAG-3/MHC class II interactions in cell-cell contacts: C.E. Demeure, et al.; Eur. J. Cancer 37, 1709 (2001), Abstract;
CD3/TCR complex-associated lymphocyte activation gene-3 molecules inhibit CD3/TCR signaling: S. Hannier, et al.; J. Immunol. 161, 4058 (1998), Abstract; Full Text
Characterization of the major histocompatibility complex class II binding site on LAG-3 protein: B. Huard, et al.; PNAS 94, 5744 (1997), Abstract; Full Text
Cellular expression and tissue distribution of the human LAG-3-encoded protein, an MHC class II ligand: B. Huard, et al.; Immunogenetics 39, 213 (1994), Abstract;
Characterization of the lymphocyte activation gene 3-encoded protein. A new ligand for human leukocyte antigen class II antigens: E. Baixeras, et al.; J. Exp. Med. 176, 327 (1992), Abstract; Full Text
Produced in CHO cells. The sequence coding for the 4 extracellular Ig-like domains of human LAG-3 (D1-D4) is fused to the Fc portion of human IgG1., ≥99% (SDS-PAGE), ELISA, Flow Cytometry | Print as PDF
